CSPC PHARMA (01093) announced that on February 25, 2026, the seller, CSPC Innovation Pharmaceutical Co., Ltd. (a non-wholly owned subsidiary of the company, stock code: 300765), entered into an equity transfer agreement with the buyer, CSPC Holding Group Co., Ltd. The agreement concerns the sale of a 30.0704% equity interest in the target company, Beijing Guoxin Huijin Co., Ltd., for a consideration of RMB 230 million. Following the completion of the disposal, the seller and the group will no longer hold any equity in the target company. The target company is primarily engaged in the operation of an omnimedia communication business platform, which is not part of the seller's core business. The disposal is based on a comprehensive assessment of the seller's actual development situation. It is expected that the disposal will help optimize the seller's resource allocation and financial structure. Furthermore, this move will enable the seller to focus on its core business and reduce operational risks, thereby achieving high-quality development, which is also beneficial for the group as a whole.